Kalmbach Thomas Peter sold $3.8M of GL

Kalmbach Thomas Peter (EVP & CFO) sold 21,000 shares of GLOBE LIFE INC. (GL) at an average of $180.06 ($179.30–$181.81, $3.78M total) across 4 trades on 2026-07-30.

Original reporting
SEC EDGAR · Kalmbach Thomas Peter
Published Jul 30, 2026, 10:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 10:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GL
Neutral
medium confidence
Mentioned
$GL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLNeutralLow
01

Why it matters

The disclosed open-market sale is a sentiment datapoint for GL but lacks accompanying company-specific news (earnings, guidance, deals, or regulatory actions).

02

Market read

Traders may briefly reassess GL sentiment due to CFO selling, but the filing alone is unlikely to drive a durable repricing without additional fundamental catalysts.

03

What to watch

The filing does not state a 10b5-1 plan, so traders may over-interpret intent; also, the article provides no context on prior grants, compensation timing, or planned liquidity needs.

Relevance 6/10Novelty 3/10Timing: filed 2026-07-30, reflects same-day insider sale

Background

The article is a Form 4 insider transaction disclosure for Globe Life Inc. (GL) by its EVP and CFO.

Company-level read

Ticker impact

$GLNeutralMedium confidence
Context

Kalmbach Thomas Peter, GL’s EVP and CFO, sold about 21,000 shares on 2026-07-30 for roughly $3.78M total value.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-on insider activity or unusual volume.

Evidence & confidence

Form 4 discloses the sale size, price range, and post-transaction holdings, but provides no new operational, financial, or regulatory information.

Market effects

No sector-level signal; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales can be tax- or diversification-driven and do not necessarily imply bearish fundamentals, especially when the sale is spread across multiple trades.

Key entities

  • Globe Life Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Kalmbach Thomas Peter

    EVP and CFO who sold shares on 2026-07-30.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BEMedAI 8/10

Why Stocks Like Bloom Energy and Globe Life Slumped

Bloom Energy (BE) fell 8% despite a 138.9% revenue increase and EPS beat, due to concerns over future revenue and capital expenditure. Globe Life (GL) dropped 8% after reporting 5.3% revenue growth and warning of FY 2026 headwinds. Comfort Systems (FIX) declined 9.26% despite strong earnings and revenue growth, citing higher material costs.

$GLMed

Globe Life Inc (GL) Q3 2026 Earnings Call Highlights: Premium Growth and Buybacks Offset

Globe Life Inc (GL) reported Q3 2026 earnings with total premium revenue up 7%, health premium revenue up 16%, and book value per share rising 23%. The company returned $210M to shareholders and expects to return near 70% of full-year net operating income. However, net income decreased 2%, life underwriting margin fell 5%, and full-year 2026 net operating EPS guidance was reduced to $15.35-$15.65. Management discussed various challenges and strategic plans during the earnings call.

$GLMed

Piper Sandler cuts Globe Life stock rating on medical claims concerns

Piper Sandler downgraded Globe Life (NYSE:GL) to Neutral, lowering its price target to $165 from $200 due to concerns over medical claims volatility. The stock trades at $168.41 with a P/E ratio of 10.97. Q3 results showed revenue of $1.6B, beating estimates, but EPS missed at $4.84. The firm cited exposure to medical claims severity and irregularity in Medicare supplement claims as key issues.